Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KAVV | ISIN: IE00B91XRN20 | Ticker-Symbol: 0PT
Tradegate
20.11.24
12:22 Uhr
13,400 Euro
-0,300
-2,19 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
PROTHENA CORPORATION PLC Chart 1 Jahr
5-Tage-Chart
PROTHENA CORPORATION PLC 5-Tage-Chart
RealtimeGeldBriefZeit
13,60013,80013:00
13,60013,80012:54

Aktuelle News zur PROTHENA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PROTHENA Aktie jetzt für 0€ handeln
13.11.Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus4
12.11.Prothena Corporation plc: Prothena Reports Third Quarter 2024 Financial Results and Business Highlights254Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash...
► Artikel lesen
12.11.Prothena Reports Third Quarter 2024 Financial Results and Business Highlights70DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation...
► Artikel lesen
12.11.PROTHENA CORP PUBLIC LTD CO - 10-Q, Quarterly Report1
11.11.Earnings Preview For Prothena Corp3
05.11.Prothena Corporation plc: Prothena to Report Third Quarter 2024 Financial Results on November 12223Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
28.10.Prothena's SWOT analysis: stock poised for growth amid clinical milestones5
04.10.Chutes & Ladders-Prothena promotes one exec while another leaves6
01.10.Breaking Down Prothena Corp: 4 Analysts Share Their Views5
01.10.Prothena shares hold buy rating with steady target amid selloff2
30.09.RBC Capital keeps Sector Perform rating on Prothena shares despite CMO exit4
30.09.Prothena's SWOT analysis: biotech stock faces high-risk, high-reward pipeline5
27.09.Prothena names Chad Swanson as new Chief Development Officer1
27.09.PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report1
27.09.Prothena Corporation plc: Prothena Announces Leadership Team Updates488Chad J. Swanson, Ph.D., appointed Chief Development Officer and will lead clinical development and medical functions Hideki Garren, MD, Ph.D., Chief Medical Officer, will pursue an opportunity...
► Artikel lesen
29.08.Prothena Corporation plc: Prothena to Participate in Upcoming Healthcare Conferences273Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
14.08.Prothena shares target cut, maintains outperform on 2Q financial results2
08.08.PROTHENA CORP PUBLIC LTD CO - S-8, Securities to be offered to employees in employee benefit plans1
08.08.Prothena GAAP EPS of $1.22 beats by $2.28, revenue of $132.01M beats by $121.28M2
08.08.Prothena Corporation plc: Prothena Reports Second Quarter 2024 Financial Results and Business Highlights741Net cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating and investing activities was $57.3 million for the first six months...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1